Tumor promotion by Mdm2 splice variants unable to bind p53

Cancer Research

Volumn 63, Issue 18, 2003, Pages 5703-5706

  Fridman, Jordan S ^a,c   Hernando, Eva ^b   Hemann, Michael T ^a   De Stanchina, Elisa ^a   Cordon Cardo, Carlos ^b   Lowe, Scott W ^a  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Experimental Station   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN MDM2; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; MOUSE; NONHUMAN; ONCOGENE MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TRANSGENIC MOUSE; TUMOR GROWTH;

ALTERNATIVE SPLICING; ANIMALS; DNA, COMPLEMENTARY; HUMANS; LYMPHOMA, B-CELL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0141706686     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Michael, D., and Oren, M. The p53-Mdm2 module and the ubiquitin system. Semin. Cancer Biol., 13: 49-58, 2003.
2. Michael, D., and Oren, M. The p53 and Mdm2 families in cancer. Curr. Opin. Genet. Dev., 12: 53-59. 2002.
3. Bartel, F., Taubert, H., and Harris, L. C. Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell, 2: 9-15, 2002.
4. Sigalas, I., Calvert, A. H., Anderson, J. J., Neal, D. E., and Lunec, J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat. Med., 2: 912-917, 1996.
5. Dang, J., Kuo, M. L., Eischen, C. M., Stepanova, L., Sherr, C. J., and Roussel, M. F. The RING domain of Mdm2 can inhibit cell proliferation. Cancer Res., 62: 1222-1230, 2002.
6. Garcia, J. F., Villuendas, R., Sanchez-Beato, M., Sanchez-Aguilera, A., Sanchez, L., Prieto, I., and Piris, M. A. Nucleolar p14(ARF) overexpression in Reed-Sternberg cells in Hodgkin's lymphoma: absence of p14(ARF)/Hdm2 complexes is associated with expression of alternatively spliced Hdm2 transcripts. Am. J. Pathol., 160: 569-578, 2002.
7. Sambrook, J., and Russell, D. (eds.). Molecular Cloning: A Laboratory Manual. 3rd edition, Vol. 1-3. Cold Spring Harbor, NY: Cold Spring Harbor Press. 2001.
8. Schmitt, C. A., Fridman, J. S., Yang, M., Baranov, E., Hoffman, R. M., and Lowe, S. W. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell, 1: 289-298. 2002.
9. de Stanchina, E., McCurrach, M. E., Zindy, F., Shieh, S. Y., Ferbeyre, G., Samuelson, A. V., Prives, C., Roussel, M. F., Sherr, C. J., and Lowe, S. W. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev., 12: 2434-2442, 1998.
10. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
11. Hemann, M. T., Fridman, J. S., Zilfou, J. T., Hernande, E., Paddison, P. J., Cordon-Cardo, C., Hannon, G. J., and Lowe, S. W. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat. Genet., 33: 396-400, 2003.
12. Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., and Brinster, R. L. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature (Lond.), 318: 533-538, 1985.
13. Eischen, C. M., Weber, J. D., Roussel, M. F., Sherr, C. J., and Cleveland, J. L. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev., 13: 2658-2669, 1999.
14. Schmitt, C. A., McCurrach, M. E., de Stanchina, E., Wallace-Brodeur, R. R., and Lowe, S. W. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev., 13: 2670-2677, 1999.
15. Harvey, D. M., and Levine, A. J. p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev., 5: 2375-2385, 1991.
16. Lowe, S. W., Jacks, T., Housman, D. E., and Ruley, H. E. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc. Natl. Acad. Sci. USA, 91: 2026-2030, 1994.
17. Evans, S. C., Viswanathan, M., Grier, J. D., Narayana, M., El-Naggar, A. K., and Lozano, G. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene, 20: 4041-4049, 2001.
18. Soengas, M. S., Alarcon, R. M., Yoshida, H., Giaccia, A. J., Hakem, R., Mak, T. W., and Lowe, S. W. Apaf-I and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science (Wash. DC), 284: 156-159, 1999.
19. Lukas, J., Gao, D. Q., Keshmeshian, M., Wen, W. H., Tsao-Wei, D., Rosenberg, S., and Press, M. F. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res., 61: 3212-3219, 2001.
20. Matsumoto, R., Tada, M., Nozaki, M., Zhang, C. L., Sawamura, Y., and Abe, H. Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms. Cancer Res., 58: 609-613, 1998.
21. Bartel, F., Meye, A., Wurl, P., Kappler, M., Bache, M., Lautenschlager, C., Grunbaum, U., Schmidt, H., and Taubert, H. Amplification of the MDM2 gene, but not expression of splice variants of MDM2 mRNA, is associated with prognosis in soft tissue sarcoma. Int. J. Cancer, 95, 168-175, 2001.
22. Brown, D. R., Thomas, C. A., and Deb, S. P. The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis. EMBO J., 17: 2513-2525, 1998.
23. Daujat, S., Neel, H., and Piette, J. MDM2: life without p53. Trends Genet., 17: 459-464, 2001.